Advanced search
Publication Cover
Clinical, Cosmetic and Investigational Dermatology Volume 15, 2022 - Issue
Submit an article Journal homepage
180
Views
4
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study

Ying Li1 Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China;2 Institute of Psoriasis, Tongji University School of Medicine, Shanghai, People’s Republic of ChinaView further author information
,
Jia-Jing Lu1 Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China;2 Institute of Psoriasis, Tongji University School of Medicine, Shanghai, People’s Republic of ChinaView further author information
,
Xiao-Yuan Zhong1 Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China;2 Institute of Psoriasis, Tongji University School of Medicine, Shanghai, People’s Republic of ChinaView further author information
,
Ying-Yuan Yu1 Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China;2 Institute of Psoriasis, Tongji University School of Medicine, Shanghai, People’s Republic of ChinaView further author information
,
Ning Yu1 Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China;2 Institute of Psoriasis, Tongji University School of Medicine, Shanghai, People’s Republic of ChinaView further author information
,
Yu Wang1 Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China;2 Institute of Psoriasis, Tongji University School of Medicine, Shanghai, People’s Republic of ChinaView further author information
,
Xue-Mei Yi1 Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China;2 Institute of Psoriasis, Tongji University School of Medicine, Shanghai, People’s Republic of ChinaView further author information
,
Yang-Feng Ding1 Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China;2 Institute of Psoriasis, Tongji University School of Medicine, Shanghai, People’s Republic of ChinaView further author information
&
Yu-Ling Shi1 Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China;2 Institute of Psoriasis, Tongji University School of Medicine, Shanghai, People’s Republic of ChinaCorrespondence[email protected] [email protected]
ORCID Iconhttps://orcid.org/0000-0002-1273-7881View further author information
ORCID Icon show all
Pages 2245-2252 | Received 01 Sep 2022, Accepted 11 Oct 2022, Published online: 20 Oct 2022

References

  • Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945–1960. doi:10.1001/jama.2020.4006
  • Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338. doi:10.1056/NEJMoa1314258
  • Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345–356. doi:10.1056/NEJMoa1512711
  • Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with Adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the Phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–417. doi:10.1016/j.jaad.2016.11.041
  • Costanzo A, Malara G, Pelucchi C, et al. Effectiveness end points in real-world studies on biological therapies in psoriasis: systematic review with focus on drug survival. Dermatology. 2018;234(1–2):1–12. doi:10.1159/000488586
  • Kishimoto M, Komine M, Kamiya K, Sugai J, Mieno M, Ohtsuki M. Drug survival of biologic agents for psoriatic patients in a real-world setting in Japan. J Dermatol. 2020;47(1):33–40. doi:10.1111/1346-8138.15146
  • Torres T, Puig L, Vender R, et al. Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: a Retrospective Multi-Country, Multicentric Cohort Study. Am J Clin Dermatol. 2021;22(4):567–579. doi:10.1007/s40257-021-00598-4
  • Menter A, Papp KA, Gooderham M, et al. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Eur Acad Dermatol Venereol. 2016;30(7):1148–1158. doi:10.1111/jdv.13611
  • Gerdes S, Asadullah K, Hoffmann M, et al. Real-world evidence from the non-interventional, prospective, German multicentre PERSIST study of patients with psoriasis after 1 year of treatment with guselkumab. J Eur Acad Dermatol Venereol. 2022;36(9):1568–1577. doi:10.1111/jdv.18218
  • Dapavo P, Siliquini N, Mastorino L, et al. Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study. J Dermatolog Treat. 2021;32:1–6. doi:10.1080/09546634.2020.1830930
  • Graier T, Salmhofer W, Jonak C, et al. Biologic drug survival rates in the era of anti-interleukin-17 antibodies: a time-period-adjusted registry analysis. Br J Dermatol. 2021;184(6):1094–1105. doi:10.1111/bjd.19701
  • Ohata C, Ohyama B, Katayama E, Nakama T. Real-world efficacy and safety of interleukin-17 inhibitors for psoriasis: a single-center experience. J Dermatol. 2020;47(4):405–408. doi:10.1111/1346-8138.15247
  • Egeberg A, Bryld LE, Skov L. Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2019;81(1):173–178. doi:10.1016/j.jaad.2019.03.048
  • Yiu ZZN, Mason KJ, Hampton PJ, et al. Drug survival of Adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Br J Dermatol. 2020;183(2):294–302. doi:10.1111/bjd.18981
  • Mourad AI, Gniadecki R. Biologic Drug Survival in Psoriasis: a Systematic Review & Comparative Meta-Analysis. Front Med. 2020;7:625755. doi:10.3389/fmed.2020.625755
  • Lockshin B, Cronin A, Harrison RW, et al. Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: the Corrona Psoriasis Registry. Dermatol Ther. 2021;34(2):e14808. doi:10.1111/dth.14808
  • Liu LF, Chen JS, Gu J, et al. Etanercept biosimilar (recombinant human tumor necrosis factor-alpha receptor II: igG Fc fusion protein) and methotrexate combination therapy in Chinese patients with moderate-to-severe plaque psoriasis: a multicentre, randomized, double-blind, placebo-controlled trial. Arch Dermatol Res. 2020;312(6):437–445. doi:10.1007/s00403-019-02024-6
  • Gniadecki R, Bang B, Bryld LE, Iversen L, Lasthein S, Skov L. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. Br J Dermatol. 2015;172(1):244–252. doi:10.1111/bjd.13343
  • Mourad A, Straube S, Armijo-Olivo S, Gniadecki R. Factors predicting persistence of biologic drugs in psoriasis: a systematic review and meta-analysis. Br J Dermatol. 2019;181(3):450–458. doi:10.1111/bjd.17738
  • Akdogan N, Dogan S, Bostan E, et al. Age and psoriatic arthritis are important predictors of biologic agent switch in psoriasis. Expert Rev Clin Pharmacol. 2021;14(12):1535–1541. doi:10.1080/17512433.2021.1979394

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.